ITMCTR2000003662尚未招募1 期
Real-world study on the treatment of stage III colorectal cancer
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 75（—）
- 性别
- All
入选标准
- •1. Meet the diagnostic criteria for stage III colorectal cancer, with clear pathological evidence.
- •2. Surgery and chemotherapy have been completed.
- •3. Between 18-75 years old (including 18 and 75 years old), there is no restriction on men and women.
- •4. KPS >= 60 points, estimated to be able to survive more than 6 months.
- •5. Bone marrow, heart, liver, and kidney functions are basically normal.
排除标准
- •1. Cases of malignant lymphoma or stromal tumor.
- •2. At the same time combined with other malignant tumors.
- •3. People with mental disorders.
- •4. Women who are pregnant or breastfeeding.
- •5. Under chemotherapy.
- •6. People with severe heart, liver, and kidney disease and dysfunction.
- •7. With severe complications (such as gastrointestinal obstruction, bleeding).
- •8. Those who are participating in other drug trials.
- •9. Allergy or discomfort to the study drug.
研究者
相似试验
招募中
1 期
An exploratory study on the treatment of stage III colon cancer with special prescription of removing dampness and removing dampness after postoperative chemotherapyColon cancerITMCTR2000003424Oncology Department, Guangdong Provincial Hospital of Chinese Medicine
招募中
1 期
Clinical study on the treatment of stage III - IV colorectal cancer of spleen deficiency and essence deficiency type with anticancer essence formulaColorectal cancerITMCTR2000003853onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
招募中
3 期
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type IIFCDfocal cortical dysplasia type IIJPRN-jRCT2031230317Kato Mituhiro20
招募中
1 期
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)Atopic dermatitis and moderate-to severe atopic hand eczemaMedDRA version: 21.1Level: LLTClassification code: 10003639Term: Atopic dermatitis Class: 10040785MedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785CTIS2022-502653-34-01EO PHARMA A/S402
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 18.1Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-FIBoehringer Ingelheim Finland Ky250